The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
Open accessAbstract
Section 3: Clinical features which predict the presence of mesothelioma Recommendations Section 4: Staging systems Recommendation Section 5: Imaging modalities for diagnosing and staging Recommendations Section 6: Pathological diagnosis Recommendations
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Exercise for the management of cancer-related fatigue in adults
Cramp, F., & Byron-Daniel, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006145.pub3 · Cited by 1,096
Higginson, I. J., Bausewein, C., Reilly, C. C., Gao, W., Gysels, M., Dzingina, M., McCrone, P., Booth, S., Jolley, C. J., & Moxham, J. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70226-7 · Cited by 605
Abernethy, A. P., Currow, D. C., Frith, P., Fazekas, B. S., McHugh, A., & Bui, C. (2003) · BMJ · doi:10.1136/bmj.327.7414.523 · Cited by 521
Farquhar, M. C., Prevost, A. T., McCrone, P., Brafman-Price, B., Bentley, A., Higginson, I. J., Todd, C., & Booth, S. (2014) · BMC Medicine · doi:10.1186/s12916-014-0194-2 · Cited by 201
Hoda, M. A., Dong, Y., Rozsas, A., Klikovits, T., Laszlo, V., Ghanim, B., Stockhammer, P., Ozsvar, J., Jakopovic, M., Samarzija, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.018 · Cited by 27
Research works printed but not linked: 232
- 10.1136/thx.2007.087619 · DOI · Paper page
- Beckett, 2015, Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales, Lung Cancer, 88, 344, 10.1016/j.lungcan.2015.03.005 · DOI
- 10.1136/thx.52.6.507 · DOI · Paper page
- Aguilar-Madrid, 2010, Case-control study of pleural mesothelioma in workers with social security in Mexico, Am J Ind Med, 53, 241, 10.1002/ajim.20780 · DOI
- 10.1023/A:1007691003600 · DOI · Paper page
- Cigognetti, 2015, BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations, Mod Pathol, 28, 1043, 10.1038/modpathol.2015.65 · DOI · Paper page
- 10.1159/000321370 · DOI
- 10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO;2-5 · doi:10.1002/1097-0142(19861001)58:7<1540::aid-cncr2820580727>3.0.co;2-5
- Rusch, 2016, The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma, J Thorac Oncol, 11, 2112, 10.1016/j.jtho.2016.09.124 · DOI · Paper page
- Sugarbaker, 1993, Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma, J Clin Oncol, 11, 1172, 10.1200/JCO.1993.11.6.1172 · DOI · Paper page
- 10.1136/thoraxjnl-2014-206054 · DOI
- Salonen, 1986, Computed tomography of pleural lesions with special reference to the mediastinal pleura, Acta Radiol Diagn, 27, 527, 10.1177/028418518602700507 · doi:10.1177/028418518602700507
- Seely, 2009, Malignant pleural mesothelioma: computed tomography and correlation with histology, Eur J Radiol, 70, 485, 10.1016/j.ejrad.2008.02.004 · DOI
- Okten, 2006, Computed tomography findings in 66 patients with malignant pleural mesothelioma due to environmental exposure to asbestos, Clin Imaging, 30, 177, 10.1016/j.clinimag.2005.12.027 · doi:10.1016/j.clinimag.2005.12.027
- 10.1080/028418501127347070 · DOI
- 10.1016/S0720-048X(01)00426-0 · DOI · Paper page
- 10.1378/chest.118.3.604 · DOI
- 10.2214/ajr.154.3.2106209 · DOI · Paper page
- Yilmaz, 2005, CT in differential diagnosis of benign and malignant pleural disease, Monaldi Arch Chest Dis, 63, 17, 10.4081/monaldi.2005.653 · doi:10.4081/monaldi.2005.653
- 10.1136/thx.2008.100545 · doi:10.1136/thx.2008.100545
- Elboga, 2012, The role of FDG PET-CT in differential diagnosis of pleural pathologies, Rev Esp Med Nucl Imagen Mol, 31, 187
- 10.1378/chest.14-0820 · DOI
- 10.1378/chest.114.3.713 · DOI · Paper page
- Abe, 2012, Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma, Oncol Rep, 27, 333
- 10.1097/JTO.0b013e3181c0a7ff · DOI
- Treglia, 2014, Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis, Acad Radiol, 21, 11, 10.1016/j.acra.2013.09.015 · doi:10.1016/j.acra.2013.09.015
- 10.1148/radiol.12110872 · DOI
- Boraschi, 1999, Magnetic resonance appearance of asbestos-related benign and malignant pleural diseases, Scand J Work Environ Health, 25, 18, 10.5271/sjweh.378 · doi:10.5271/sjweh.378
- Revelli M , Chiesa F , Del Prato A , et al . Role of respiratory-triggered diffusion-weighted MRI in the assessment of pleural disease. Br J Radiol 2016. doi:10.1259/bjr.20160289. [Epub ahead of print 29 Jun 2016]. · doi:10.1259/bjr.20160289
- 10.2214/AJR.09.3519 · DOI
- Coolen, 2015, Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging, Radiology, 274, 576, 10.1148/radiol.14132111 · doi:10.1148/radiol.14132111
- 10.1378/chest.129.6.1570 · DOI
- 10.3816/CLC.2009.n.033 · DOI
- 10.1097/RLI.0b013e3181817b3d · DOI
- 10.1016/S1010-7940(03)00609-2 · DOI
- 10.1016/S0003-4975(03)00010-9 · doi:10.1016/s0003-4975(03)00010-9
- 10.2214/ajr.172.4.10587144 · DOI · Paper page
- Niccoli-Asabella, 2013, 18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up), Clin Imaging, 37, 1098, 10.1016/j.clinimag.2013.06.009 · doi:10.1016/j.clinimag.2013.06.009
- 10.1016/S0169-5002(98)00083-X · doi:10.1016/s0169-5002(98)00083-x
- 10.2214/ajr.159.5.1414807 · doi:10.2214/ajr.159.5.1414807
- Erasmus, 2005, Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications, J Thorac Cardiovasc Surg, 129, 1364, 10.1016/j.jtcvs.2004.10.034 · DOI · Paper page
- Fiore, 2006, Imaging before and after multimodal treatment for malignant pleural mesothelioma, Radiol Med, 111, 355, 10.1007/s11547-006-0034-3 · doi:10.1007/s11547-006-0034-3
- 10.1016/S0022-5223(03)00207-1 · DOI · Paper page
- Frauenfelder, 2015, Use of Computed Tomography and Positron Emission Tomography/Computed Tomography for Staging of Local Extent in Patients With Malignant Pleural Mesothelioma, J Comput Assist Tomogr, 39, 160, 10.1097/RCT.0000000000000174 · doi:10.1097/rct.0000000000000174
- 10.7785/tcrt.2012.500245 · doi:10.7785/tcrt.2012.500245
- Martini, 2016, Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma, Lung Cancer, 94, 40, 10.1016/j.lungcan.2016.01.017 · doi:10.1016/j.lungcan.2016.01.017
- Pinelli, 2015, Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?, Respiration, 89, 558, 10.1159/000381922 · doi:10.1159/000381922
- 10.1510/icvts.2010.255893 · DOI
- 10.1510/icvts.2010.255901 · doi:10.1510/icvts.2010.255901
- 10.1016/j.jtho.2015.11.005 · DOI · Paper page
- 10.5858/arpa.2012-0214-OA · DOI · Paper page
- 10.1309/AJCPT94JVWIHBKRD · DOI
- Hida, 2015, Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue, Cancer Sci, 106, 1635, 10.1111/cas.12769 · DOI
- Walters, 2011, Biopsy techniques for the diagnosis of mesothelioma, Recent Results Cancer Res, 189, 45, 10.1007/978-3-642-10862-4_4 · doi:10.1007/978-3-642-10862-4_4
- 10.1097/PAT.0b013e32835bc848 · DOI
- Cui A , Jin XG , Zhai K , et al . Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 2014;4:e004145. · DOI
- Hu, 2014, Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis, Clin Chim Acta, 433, 44, 10.1016/j.cca.2014.02.024 · DOI
- Lin, 2014, Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis, Int J Clin Exp Med, 7, 1289
- Kirschner, 2015, Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis, Br J Cancer, 113, 963, 10.1038/bjc.2015.286 · DOI
- 10.1158/1078-0432.CCR-10-1929 · DOI
- Creaney, 2013, Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma, Lung Cancer, 82, 491, 10.1016/j.lungcan.2013.09.016 · DOI
- 10.1155/2012/430689 · DOI
- 10.1038/bjc.2013.815 · DOI
- 10.1164/rccm.200807-1125OC · DOI
- Hirayama, 2011, Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma, Respir Med, 105, 137, 10.1016/j.rmed.2010.10.010 · DOI
- 10.1097/JTO.0b013e3182272294 · DOI
- 10.1097/JTO.0b013e31822a3740 · DOI
- 10.1016/j.lungcan.2011.06.007 · DOI
- 10.1097/JTO.0b013e31823f45c1 · DOI
- Thylén, 2001, Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma, Cancer, 92, 1224, 10.1002/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U · DOI
- 10.1200/JCO.2009.26.9944 · DOI
- 10.1186/1756-9966-32-7 · DOI
- Hooper, 2015, The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication, Br J Cancer, 112, 1175, 10.1038/bjc.2015.62 · DOI
- 10.1164/rccm.200802-258OC · DOI
- Filiberti, 2014, Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos, Oncology, 86, 33, 10.1159/000355687 · DOI
- Bayram, 2014, Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos, Lung, 192, 197, 10.1007/s00408-013-9526-9 · DOI
- 10.1007/s00204-010-0580-2 · DOI
- 10.1158/1055-9965.EPI-08-0422 · doi:10.1158/1055-9965.epi-08-0422
- 10.1200/JCO.2007.12.5294 · doi:10.1200/jco.2007.12.5294
- Curran, 1998, Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience, J Clin Oncol, 16, 145, 10.1200/JCO.1998.16.1.145 · DOI · Paper page
- 10.1200/JCO.2005.07.050 · DOI
- 10.1038/bjc.2013.504 · DOI
- 10.1136/thorax.55.9.731 · DOI · Paper page
- 10.1378/chest.113.3.723 · DOI · Paper page
- 10.1136/thoraxjnl-2014-205285 · DOI · Paper page
- Brims, 2016, A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis, J Thorac Oncol, 11, 573, 10.1016/j.jtho.2015.12.108 · DOI · Paper page
- Gemba, 2013, Treatment and survival analyses of malignant mesothelioma in Japan, Acta Oncol, 52, 803, 10.3109/0284186X.2012.709948 · DOI
- 10.1097/JTO.0b013e3181f1cf2b · DOI · Paper page
- 10.1016/j.athoracsur.2014.04.040 · DOI
- 10.1016/S0140-6736(14)60418-9 · DOI · Paper page
- 10.1001/jama.2012.5535 · DOI · Paper page
- 10.1136/thoraxjnl-2012-203043 · doi:10.1136/thoraxjnl-2012-203043
- 10.1007/s00408-011-9283-6 · DOI
- 10.1111/j.1440-1843.2005.00763.x · doi:10.1111/j.1440-1843.2005.00763.x
- Brancatisano, 1991, Pleurectomy for mesothelioma, Med J Aust, 154, 455, 10.5694/j.1326-5377.1991.tb121175.x · doi:10.5694/j.1326-5377.1991.tb121175.x
- 10.1186/1749-8090-5-27 · doi:10.1186/1749-8090-5-27
- Basso, 2012, Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results, Anticancer Res, 32, 5131
- 10.1016/j.lungcan.2009.02.023 · DOI
- 10.1097/JTO.0b013e3182208e3f · DOI · Paper page
- 10.1016/S1470-2045(11)70149-8 · DOI · Paper page
- 10.1016/j.athoracsur.2012.05.102 · doi:10.1016/j.athoracsur.2012.05.102
- Bölükbas, 2012, Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma, J Thorac Oncol, 7, 900, 10.1097/JTO.0b013e31824de2dc · doi:10.1097/jto.0b013e31824de2dc
- Burkholder, 2015, Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma, Ann Thorac Surg, 99, 1775, 10.1016/j.athoracsur.2015.01.058 · DOI
- 10.1177/0218492312454017 · DOI
- 10.1097/JTO.0b013e3181ed0489 · DOI
- Cao, 2012, Systematic review of trimodality therapy for patients with malignant pleural mesothelioma, Ann Cardiothorac Surg, 1, 428
- 10.1016/j.lungcan.2013.04.024 · doi:10.1016/j.lungcan.2013.04.024
- 10.1016/j.lungcan.2013.11.026 · DOI · Paper page
- Lim, 2016, A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study, Lung Cancer, 91, S71, 10.1016/S0169-5002(16)30212-4 · doi:10.1016/s0169-5002(16)30212-4
- 10.1097/JTO.0b013e318286c72b · doi:10.1097/jto.0b013e318286c72b
- 10.1016/j.athoracsur.2014.09.056 · DOI · Paper page
- 10.1200/JCO.20005.14.589 · DOI · Paper page
- 10.1016/S0140-6736(08)60727-8 · DOI · Paper page
- Mordant, 2008, MVP and vinorelbine for malignant pleural mesothelioma, Lancet, 372, 629, 10.1016/S0140-6736(08)61273-8 · doi:10.1016/s0140-6736(08)61273-8
- Zalcman, 2015, Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial, J of Clinical Oncology, 33, 7500, 10.1200/jco.2015.33.15_suppl.7500 · DOI
- 10.1097/JTO.0b013e31817c73d6 · DOI · Paper page
- Buikhuisen, 2015, Second line therapy in malignant pleural mesothelioma: A systematic review, Lung Cancer, 89, 223, 10.1016/j.lungcan.2015.06.018 · DOI
- 10.1200/JCO.2006.09.9887 · DOI · Paper page
- 10.1016/S1470-2045(15)70056-2 · DOI · Paper page
- Thapa, 2017, The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma, J Thorac Oncol, 12, 850, 10.1016/j.jtho.2017.02.013 · DOI
- Alley, 2017, Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial, Lancet Oncol, 18, 623, 10.1016/S1470-2045(17)30169-9 · DOI · Paper page
- 10.1378/chest.108.3.754 · DOI · Paper page
- 10.1038/sj.bjc.6601957 · DOI · Paper page
- 10.1016/j.radonc.2007.05.022 · DOI · Paper page
- 10.1016/S1470-2045(16)30095-X · DOI · Paper page
- 10.1016/j.lungcan.2009.06.014 · DOI
- Bayman N , Ardron D , Ashcroft L , et al . Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. BMJ Open 2016;6:e010589. · DOI
- de Perrot, 2016, Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 151, 468, 10.1016/j.jtcvs.2015.09.129 · DOI
- 10.1183/09031936.96.09122565 · DOI
- 10.1016/j.ijrobp.2014.05.032 · doi:10.1016/j.ijrobp.2014.05.032
- 10.1016/j.ijrobp.2006.03.012 · DOI · Paper page
- 10.1016/j.ijrobp.2007.02.047 · DOI
- Bille, 2012, Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospitals, Gen Thorac Cardiovasc Surg, 60, 289, 10.1007/s11748-011-0915-9 · DOI
- 10.1016/j.lungcan.2009.08.019 · DOI
- 10.1097/01243894-200605000-00004 · doi:10.1097/01243894-200605000-00004
- 10.1016/j.radonc.2009.03.011 · doi:10.1016/j.radonc.2009.03.011
- 10.1097/JTO.0b013e318031d05c · DOI
- Minatel, 2012, Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung, J Thorac Oncol, 7, 1862, 10.1097/JTO.0b013e318272601f · doi:10.1097/jto.0b013e318272601f
- 10.1016/j.lungcan.2013.10.013 · DOI
- 10.1016/j.ijrobp.2007.03.011 · DOI
- Pagan, 2006, 5-year prospective results of trimodality treatment for malignant pleural mesothelioma, J Cardiovasc Surg, 47, 595
- 10.1067/mtc.2001.116560 · DOI · Paper page
- Tonoli, 2011, Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series, Radiother Oncol, 101, 311, 10.1016/j.radonc.2011.09.025 · DOI
- 10.1183/09031936.00039510 · DOI · Paper page
- 10.1093/annonc/mdm093 · DOI · Paper page
- 10.1016/S1470-2045(15)00208-9 · DOI · Paper page
- 10.1200/JCO.2016.67.2675 · DOI · Paper page
- 10.1016/S0936-6555(05)80582-5 · DOI
- 10.1097/JTO.0000000000000499 · DOI
- 10.1111/j.1440-1673.1994.tb00177.x · DOI
- 10.1016/S0360-3016(98)00409-X · DOI
- 10.1016/j.ejca.2011.05.012 · DOI
- Chapman E , Berenstein EG , Dieguez M , et al . Radiotherapy for malignant pleural mesothelioma. Cochrane Database Syst Rev 2006;3:CD003880. · DOI
- 10.1016/j.lungcan.2013.11.004 · DOI
- 10.1136/thx.54.3.238 · doi:10.1136/thx.54.3.238
- 10.1016/j.ejca.2008.08.009 · DOI
- Taylor, 2013, Benefits of multidisciplinary teamwork in the management of breast cancer, Breast Cancer, 5, 79
- 10.1200/JOP.2014.003350 · DOI · Paper page
- 10.1038/bjc.2013.231 · DOI
- Bibby AC , Williams K , Smith S , et al . What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK. BMJ Open 2016;6:e012092. · doi:10.1136/bmjopen-2016-012092
- Granieri, 2013, Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers, Neuropsychiatr Dis Treat, 9, 1193
- Arber, 2013, ’It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma, Psychooncology, 22, 1528, 10.1002/pon.3162 · DOI
- Clayson, 2005, Mesothelioma from the patient’s perspective, Hematol Oncol Clin North Am, 19, 1175, 10.1016/j.hoc.2005.09.003 · DOI
- Ball, 2016, A systematic literature review comparing the psychological care needs of patients with mesothelioma and advanced lung cancer, Eur J Oncol Nurs, 25, 62, 10.1016/j.ejon.2016.09.007 · DOI
- Moore, 2008, ’Hands of Time’: the experience of establishing a support group for people affected by mesothelioma, Eur J Cancer Care, 17, 585
- Chamming’s, 2013, Compensation of pleural mesothelioma in France: data from the French National Mesothelioma Surveillance Programme, Am J Ind Med, 56, 146, 10.1002/ajim.22106 · doi:10.1002/ajim.22106
- 10.1002/ajim.20705 · doi:10.1002/ajim.20705
- Kuschner, 2012, Missed opportunities to counsel patients with malignant pleural mesothelioma about causation and potential compensation, Am J Med Sci, 343, 206, 10.1097/MAJ.0b013e3182297912 · doi:10.1097/maj.0b013e3182297912
- 10.1016/j.ejrad.2009.02.002 · DOI
- 10.1097/JTO.0000000000000211 · doi:10.1097/jto.0000000000000211
- 10.1093/annonc/mdh059 · DOI · Paper page
- 10.1200/JCO.2006.06.8999 · DOI · Paper page
- 10.1183/09031936.00146110 · DOI
- Hilmi Ozden, 2007, Mustaffer Metintas Relationship between tumour size of MPM and its response to chemotherapy, Journal of Health Science, 53, 23, 10.1248/jhs.53.23 · doi:10.1248/jhs.53.23
- Nowak, 2005, CT, RECIST, and malignant pleural mesothelioma, Lung Cancer, 49, S37, 10.1016/j.lungcan.2005.03.030 · DOI
- 10.1007/s00330-008-0918-9 · DOI
- 10.1016/S0169-5002(03)00292-7 · DOI
- 10.1093/annonc/mdh059 · DOI · Paper page
- 10.1007/s00330-008-0918-9 · DOI
- 10.1097/00000478-200101000-00004 · DOI
- 10.1080/00313020802579250 · doi:10.1080/00313020802579250
- 10.1046/j.1365-2559.2003.01583.x · DOI
- Ordóñez, 2013, Mesothelioma with signet-ring cell features: report of 23 cases, Mod Pathol, 26, 370, 10.1038/modpathol.2012.172 · DOI
- 10.1309/QHCA-8594-TA7P-0DVQ · doi:10.1309/qhca-8594-ta7p-0dvq
- 10.1097/00000478-200604000-00006 · doi:10.1097/00000478-200604000-00006
- 10.1053/hupa.2001.24329 · doi:10.1053/hupa.2001.24329
- 10.1002/(SICI)1096-9896(199910)189:2<251::AID-PATH412>3.0.CO;2-F · doi:10.1002/(sici)1096-9896(199910)189:2<251::aid-path412>3.0.co;2-f
- 10.1038/modpathol.3880018 · DOI · Paper page
- 10.1111/j.1365-2559.2009.03298.x · DOI
- 10.1309/XL6K-8E62-9FLD-V8Q8 · doi:10.1309/xl6k-8e62-9fld-v8q8
- 10.1002/cncr.22477 · DOI
- 10.1097/00000478-200302000-00002 · doi:10.1097/00000478-200302000-00002
- 10.1046/j.1365-2559.1998.00349.x · doi:10.1046/j.1365-2559.1998.00349.x
- 10.1038/modpathol.2009.180 · DOI
- Gotzos, 1996, The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type, Pathol Res Pract, 192, 137, 10.1016/S0344-0338(96)80208-1 · DOI
- Attanoos, 1996, Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma, Histopathology, 29, 209, 10.1111/j.1365-2559.1996.tb01393.x · doi:10.1111/j.1365-2559.1996.tb01393.x
- 10.1016/0046-8177(93)90080-Z · doi:10.1016/0046-8177(93)90080-z
- Collins, 1992, Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma, Am J Pathol, 141, 827
- Dejmek, 1997, Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma, APMIS, 105, 889, 10.1111/j.1699-0463.1997.tb05099.x · doi:10.1111/j.1699-0463.1997.tb05099.x
- 10.1002/dc.20202 · doi:10.1002/dc.20202
200 of 232 shown
Cited by
Scherpereel, A., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30765-4 · Cited by 454
British Thoracic Society Guideline for pleural disease
Roberts, M. E., Rahman, N. M., Maskell, N. A., Bibby, A. C., Blyth, K. G., Corcoran, J. P., Edey, A., Evison, M., de Fonseka, D., Hallifax, R., et al. (2023) · Thorax · doi:10.1136/thorax-2022-219784 · Cited by 338
Self-citationERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273
Self-citationUpdate on biology and management of mesothelioma
Asciak, R., George, V., & Rahman, N. M. (2021) · European Respiratory Review · doi:10.1183/16000617.0226-2020 · Cited by 75
Self-citationThe Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70
Metadata
- Authors
- Woolhouse, I., Bishop, L., Darlison, L., De Fonseka, D., Edey, A., Edwards, J., Faivre-Finn, C., Fennell, D. A., Holmes, S., Kerr, K. M., Nakas, A., Peel, T., Rahman, N. M., Slade, M., Steele, J., Tsim, S., & Maskell, N. A.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2018-02-14
- Volume
- 73
- Issue
- Suppl 1
- Pages
- i1-i30
- ISSN
- 0040-6376 (ISSN-L)
- 1468-3296
- OpenAlex
- W2789139181
- Cited by
- 221
- References
- 7
- FWCI
- 19.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. https://app.cochat.ai/papers/10.1136/thoraxjnl-2017-211321
- The paper
- Woolhouse, I., Bishop, L., Darlison, L., De Fonseka, D., Edey, A., Edwards, J., Faivre-Finn, C., Fennell, D. A., Holmes, S., Kerr, K. M., Nakas, A., Peel, T., Rahman, N. M., Slade, M., Steele, J., Tsim, S., & Maskell, N. A. (2018). British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. https://doi.org/10.1136/thoraxjnl-2017-211321
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.